Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459602 | 0.87 | — | — | |
| SCHEMBL5451997 | 0.82 | RIPK1 (0.35) | RAF1BRAF | |
| SCHEMBL5450823 | 0.79 | KDR (0.34) | KDRRAF1BRAF | |
| SCHEMBL5456251 | 0.72 | RIPK1 (0.37) | RAF1BRAF | |
| SCHEMBL5450095 | 0.71 | KDR (0.44) | KDRRAF1BRAF | |
| SCHEMBL14521447 | 0.70 | POLB (0.41) | KDR | |
| SCHEMBL5456280 | 0.69 | PTGES (0.32) | — | |
| SCHEMBL5455204 | 0.69 | RIPK1 (0.34) | — | |
| SCHEMBL5899278 | 0.69 | KDR (0.45) | KDRRAF1BRAF | |
| SCHEMBL5456884 | 0.66 | NPC1 (0.46) | KDRRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| EP-1656377-A1 | AMINOBENZIMIDAZOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-05-17 | — | — | EP | claimed |
| WO-2005019216-A1 | AMINOBENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | TIE1, KDR, FLT1 | KDR 2/4885RAF1 17/4885BRAF 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.